nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—UGT1A1—hematologic cancer	0.392	1	CbGaD
Ezogabine—UGT1A1—Nilotinib—hematologic cancer	0.0544	0.184	CbGbCtD
Ezogabine—CYP2A6—Methoxsalen—hematologic cancer	0.051	0.173	CbGbCtD
Ezogabine—UGT1A9—Irinotecan—hematologic cancer	0.0457	0.155	CbGbCtD
Ezogabine—UGT1A1—Irinotecan—hematologic cancer	0.0374	0.127	CbGbCtD
Ezogabine—CYP2A6—Ifosfamide—hematologic cancer	0.0372	0.126	CbGbCtD
Ezogabine—UGT1A1—Etoposide—hematologic cancer	0.0299	0.101	CbGbCtD
Ezogabine—CYP2A6—Prednisolone—hematologic cancer	0.0248	0.0841	CbGbCtD
Ezogabine—CYP2A6—Dexamethasone—hematologic cancer	0.0146	0.0496	CbGbCtD
Ezogabine—UGT1A4—hematopoietic system—hematologic cancer	0.00184	0.165	CbGeAlD
Ezogabine—KCNQ4—testis—hematologic cancer	0.00137	0.123	CbGeAlD
Ezogabine—KCNQ2—gonad—hematologic cancer	0.00137	0.122	CbGeAlD
Ezogabine—UGT1A4—blood—hematologic cancer	0.00122	0.109	CbGeAlD
Ezogabine—KCNQ3—lung—hematologic cancer	0.00113	0.102	CbGeAlD
Ezogabine—UGT1A1—hematopoietic system—hematologic cancer	0.00106	0.0948	CbGeAlD
Ezogabine—KCNQ2—testis—hematologic cancer	0.000985	0.0882	CbGeAlD
Ezogabine—KCNQ5—lymph node—hematologic cancer	0.000967	0.0865	CbGeAlD
Ezogabine—UGT1A1—blood—hematologic cancer	0.000702	0.0628	CbGeAlD
Ezogabine—CYP2A6—lung—hematologic cancer	0.000519	0.0464	CbGeAlD
Ezogabine—Alopecia—Prednisone—hematologic cancer	5.75e-05	0.000268	CcSEcCtD
Ezogabine—Dizziness—Thalidomide—hematologic cancer	5.75e-05	0.000267	CcSEcCtD
Ezogabine—Somnolence—Etoposide—hematologic cancer	5.74e-05	0.000267	CcSEcCtD
Ezogabine—Hepatobiliary disease—Methotrexate—hematologic cancer	5.73e-05	0.000267	CcSEcCtD
Ezogabine—Nausea—Bortezomib—hematologic cancer	5.72e-05	0.000266	CcSEcCtD
Ezogabine—Loss of consciousness—Dexamethasone—hematologic cancer	5.72e-05	0.000266	CcSEcCtD
Ezogabine—Loss of consciousness—Betamethasone—hematologic cancer	5.72e-05	0.000266	CcSEcCtD
Ezogabine—Asthenia—Vincristine—hematologic cancer	5.72e-05	0.000266	CcSEcCtD
Ezogabine—Paraesthesia—Prednisolone—hematologic cancer	5.72e-05	0.000266	CcSEcCtD
Ezogabine—Mental disorder—Prednisone—hematologic cancer	5.7e-05	0.000265	CcSEcCtD
Ezogabine—Nausea—Bleomycin—hematologic cancer	5.68e-05	0.000264	CcSEcCtD
Ezogabine—Infestation—Epirubicin—hematologic cancer	5.67e-05	0.000264	CcSEcCtD
Ezogabine—Infestation NOS—Epirubicin—hematologic cancer	5.67e-05	0.000264	CcSEcCtD
Ezogabine—Malnutrition—Prednisone—hematologic cancer	5.67e-05	0.000264	CcSEcCtD
Ezogabine—Rash—Thiotepa—hematologic cancer	5.67e-05	0.000263	CcSEcCtD
Ezogabine—Dermatitis—Thiotepa—hematologic cancer	5.66e-05	0.000263	CcSEcCtD
Ezogabine—Hyperhidrosis—Triamcinolone—hematologic cancer	5.66e-05	0.000263	CcSEcCtD
Ezogabine—Nausea—Vinorelbine—hematologic cancer	5.59e-05	0.00026	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Etoposide—hematologic cancer	5.57e-05	0.000259	CcSEcCtD
Ezogabine—Asthenia—Mitoxantrone—hematologic cancer	5.57e-05	0.000259	CcSEcCtD
Ezogabine—Asthenia—Irinotecan—hematologic cancer	5.57e-05	0.000259	CcSEcCtD
Ezogabine—Fatigue—Etoposide—hematologic cancer	5.56e-05	0.000259	CcSEcCtD
Ezogabine—Anxiety—Dexamethasone—hematologic cancer	5.52e-05	0.000257	CcSEcCtD
Ezogabine—Anxiety—Betamethasone—hematologic cancer	5.52e-05	0.000257	CcSEcCtD
Ezogabine—Dizziness—Carmustine—hematologic cancer	5.52e-05	0.000257	CcSEcCtD
Ezogabine—Constipation—Etoposide—hematologic cancer	5.52e-05	0.000257	CcSEcCtD
Ezogabine—Neutropenia—Doxorubicin—hematologic cancer	5.51e-05	0.000256	CcSEcCtD
Ezogabine—Dysuria—Doxorubicin—hematologic cancer	5.51e-05	0.000256	CcSEcCtD
Ezogabine—Rash—Thalidomide—hematologic cancer	5.48e-05	0.000255	CcSEcCtD
Ezogabine—Discomfort—Betamethasone—hematologic cancer	5.48e-05	0.000255	CcSEcCtD
Ezogabine—Discomfort—Dexamethasone—hematologic cancer	5.48e-05	0.000255	CcSEcCtD
Ezogabine—Dermatitis—Thalidomide—hematologic cancer	5.47e-05	0.000255	CcSEcCtD
Ezogabine—Dizziness—Alitretinoin—hematologic cancer	5.47e-05	0.000254	CcSEcCtD
Ezogabine—Asthenia—Gemcitabine—hematologic cancer	5.42e-05	0.000252	CcSEcCtD
Ezogabine—Haematuria—Epirubicin—hematologic cancer	5.41e-05	0.000252	CcSEcCtD
Ezogabine—Dizziness—Ifosfamide—hematologic cancer	5.4e-05	0.000251	CcSEcCtD
Ezogabine—Urinary tract disorder—Methotrexate—hematologic cancer	5.37e-05	0.00025	CcSEcCtD
Ezogabine—Hepatobiliary disease—Epirubicin—hematologic cancer	5.37e-05	0.000249	CcSEcCtD
Ezogabine—Weight increased—Doxorubicin—hematologic cancer	5.36e-05	0.000249	CcSEcCtD
Ezogabine—Vision blurred—Prednisone—hematologic cancer	5.34e-05	0.000248	CcSEcCtD
Ezogabine—Nausea—Thiotepa—hematologic cancer	5.34e-05	0.000248	CcSEcCtD
Ezogabine—Urethral disorder—Methotrexate—hematologic cancer	5.33e-05	0.000248	CcSEcCtD
Ezogabine—Feeling abnormal—Etoposide—hematologic cancer	5.32e-05	0.000247	CcSEcCtD
Ezogabine—Infection—Dexamethasone—hematologic cancer	5.28e-05	0.000245	CcSEcCtD
Ezogabine—Infection—Betamethasone—hematologic cancer	5.28e-05	0.000245	CcSEcCtD
Ezogabine—Dizziness—Vincristine—hematologic cancer	5.27e-05	0.000245	CcSEcCtD
Ezogabine—Rash—Carmustine—hematologic cancer	5.26e-05	0.000245	CcSEcCtD
Ezogabine—Ill-defined disorder—Prednisone—hematologic cancer	5.26e-05	0.000245	CcSEcCtD
Ezogabine—Dermatitis—Carmustine—hematologic cancer	5.26e-05	0.000245	CcSEcCtD
Ezogabine—Paraesthesia—Triamcinolone—hematologic cancer	5.26e-05	0.000244	CcSEcCtD
Ezogabine—Infestation NOS—Doxorubicin—hematologic cancer	5.25e-05	0.000244	CcSEcCtD
Ezogabine—Infestation—Doxorubicin—hematologic cancer	5.25e-05	0.000244	CcSEcCtD
Ezogabine—Feeling abnormal—Prednisolone—hematologic cancer	5.25e-05	0.000244	CcSEcCtD
Ezogabine—Visual impairment—Methotrexate—hematologic cancer	5.24e-05	0.000244	CcSEcCtD
Ezogabine—Shock—Betamethasone—hematologic cancer	5.23e-05	0.000243	CcSEcCtD
Ezogabine—Shock—Dexamethasone—hematologic cancer	5.23e-05	0.000243	CcSEcCtD
Ezogabine—Dyspnoea—Triamcinolone—hematologic cancer	5.22e-05	0.000243	CcSEcCtD
Ezogabine—Rash—Alitretinoin—hematologic cancer	5.21e-05	0.000242	CcSEcCtD
Ezogabine—Nervous system disorder—Dexamethasone—hematologic cancer	5.21e-05	0.000242	CcSEcCtD
Ezogabine—Nervous system disorder—Betamethasone—hematologic cancer	5.21e-05	0.000242	CcSEcCtD
Ezogabine—Dermatitis—Alitretinoin—hematologic cancer	5.21e-05	0.000242	CcSEcCtD
Ezogabine—Thrombocytopenia—Dexamethasone—hematologic cancer	5.2e-05	0.000242	CcSEcCtD
Ezogabine—Thrombocytopenia—Betamethasone—hematologic cancer	5.2e-05	0.000242	CcSEcCtD
Ezogabine—Nausea—Thalidomide—hematologic cancer	5.16e-05	0.00024	CcSEcCtD
Ezogabine—Dyspepsia—Triamcinolone—hematologic cancer	5.15e-05	0.00024	CcSEcCtD
Ezogabine—Rash—Ifosfamide—hematologic cancer	5.15e-05	0.00024	CcSEcCtD
Ezogabine—Dermatitis—Ifosfamide—hematologic cancer	5.15e-05	0.000239	CcSEcCtD
Ezogabine—Hyperhidrosis—Dexamethasone—hematologic cancer	5.14e-05	0.000239	CcSEcCtD
Ezogabine—Hyperhidrosis—Betamethasone—hematologic cancer	5.14e-05	0.000239	CcSEcCtD
Ezogabine—Dizziness—Irinotecan—hematologic cancer	5.13e-05	0.000239	CcSEcCtD
Ezogabine—Malaise—Prednisone—hematologic cancer	5.11e-05	0.000238	CcSEcCtD
Ezogabine—Vertigo—Prednisone—hematologic cancer	5.09e-05	0.000237	CcSEcCtD
Ezogabine—Eye disorder—Methotrexate—hematologic cancer	5.09e-05	0.000236	CcSEcCtD
Ezogabine—Syncope—Prednisone—hematologic cancer	5.08e-05	0.000236	CcSEcCtD
Ezogabine—Asthenia—Cisplatin—hematologic cancer	5.06e-05	0.000235	CcSEcCtD
Ezogabine—Fatigue—Triamcinolone—hematologic cancer	5.05e-05	0.000235	CcSEcCtD
Ezogabine—Urinary tract disorder—Epirubicin—hematologic cancer	5.03e-05	0.000234	CcSEcCtD
Ezogabine—Rash—Vincristine—hematologic cancer	5.02e-05	0.000234	CcSEcCtD
Ezogabine—Dermatitis—Vincristine—hematologic cancer	5.02e-05	0.000233	CcSEcCtD
Ezogabine—Oedema peripheral—Epirubicin—hematologic cancer	5.02e-05	0.000233	CcSEcCtD
Ezogabine—Haematuria—Doxorubicin—hematologic cancer	5e-05	0.000233	CcSEcCtD
Ezogabine—Urethral disorder—Epirubicin—hematologic cancer	4.99e-05	0.000232	CcSEcCtD
Ezogabine—Loss of consciousness—Prednisone—hematologic cancer	4.98e-05	0.000232	CcSEcCtD
Ezogabine—Hepatobiliary disease—Doxorubicin—hematologic cancer	4.96e-05	0.000231	CcSEcCtD
Ezogabine—Nausea—Carmustine—hematologic cancer	4.96e-05	0.000231	CcSEcCtD
Ezogabine—Nausea—Alitretinoin—hematologic cancer	4.91e-05	0.000228	CcSEcCtD
Ezogabine—Visual impairment—Epirubicin—hematologic cancer	4.91e-05	0.000228	CcSEcCtD
Ezogabine—Rash—Mitoxantrone—hematologic cancer	4.89e-05	0.000228	CcSEcCtD
Ezogabine—Rash—Irinotecan—hematologic cancer	4.89e-05	0.000228	CcSEcCtD
Ezogabine—Dermatitis—Mitoxantrone—hematologic cancer	4.89e-05	0.000227	CcSEcCtD
Ezogabine—Dermatitis—Irinotecan—hematologic cancer	4.89e-05	0.000227	CcSEcCtD
Ezogabine—Nausea—Ifosfamide—hematologic cancer	4.85e-05	0.000226	CcSEcCtD
Ezogabine—Feeling abnormal—Triamcinolone—hematologic cancer	4.82e-05	0.000224	CcSEcCtD
Ezogabine—Anxiety—Prednisone—hematologic cancer	4.81e-05	0.000224	CcSEcCtD
Ezogabine—Alopecia—Methotrexate—hematologic cancer	4.81e-05	0.000224	CcSEcCtD
Ezogabine—Paraesthesia—Dexamethasone—hematologic cancer	4.77e-05	0.000222	CcSEcCtD
Ezogabine—Paraesthesia—Betamethasone—hematologic cancer	4.77e-05	0.000222	CcSEcCtD
Ezogabine—Discomfort—Prednisone—hematologic cancer	4.77e-05	0.000222	CcSEcCtD
Ezogabine—Mental disorder—Methotrexate—hematologic cancer	4.77e-05	0.000222	CcSEcCtD
Ezogabine—Rash—Gemcitabine—hematologic cancer	4.77e-05	0.000222	CcSEcCtD
Ezogabine—Dermatitis—Gemcitabine—hematologic cancer	4.76e-05	0.000221	CcSEcCtD
Ezogabine—Eye disorder—Epirubicin—hematologic cancer	4.76e-05	0.000221	CcSEcCtD
Ezogabine—Malnutrition—Methotrexate—hematologic cancer	4.74e-05	0.00022	CcSEcCtD
Ezogabine—Nausea—Vincristine—hematologic cancer	4.73e-05	0.00022	CcSEcCtD
Ezogabine—Dyspepsia—Dexamethasone—hematologic cancer	4.68e-05	0.000217	CcSEcCtD
Ezogabine—Dyspepsia—Betamethasone—hematologic cancer	4.68e-05	0.000217	CcSEcCtD
Ezogabine—Urinary tract disorder—Doxorubicin—hematologic cancer	4.65e-05	0.000216	CcSEcCtD
Ezogabine—Oedema peripheral—Doxorubicin—hematologic cancer	4.64e-05	0.000216	CcSEcCtD
Ezogabine—Asthenia—Etoposide—hematologic cancer	4.63e-05	0.000215	CcSEcCtD
Ezogabine—Urethral disorder—Doxorubicin—hematologic cancer	4.62e-05	0.000215	CcSEcCtD
Ezogabine—Nausea—Irinotecan—hematologic cancer	4.61e-05	0.000214	CcSEcCtD
Ezogabine—Nausea—Mitoxantrone—hematologic cancer	4.61e-05	0.000214	CcSEcCtD
Ezogabine—Infection—Prednisone—hematologic cancer	4.6e-05	0.000214	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.59e-05	0.000213	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.59e-05	0.000213	CcSEcCtD
Ezogabine—Fatigue—Dexamethasone—hematologic cancer	4.58e-05	0.000213	CcSEcCtD
Ezogabine—Fatigue—Betamethasone—hematologic cancer	4.58e-05	0.000213	CcSEcCtD
Ezogabine—Shock—Prednisone—hematologic cancer	4.55e-05	0.000212	CcSEcCtD
Ezogabine—Visual impairment—Doxorubicin—hematologic cancer	4.54e-05	0.000211	CcSEcCtD
Ezogabine—Nervous system disorder—Prednisone—hematologic cancer	4.54e-05	0.000211	CcSEcCtD
Ezogabine—Alopecia—Epirubicin—hematologic cancer	4.5e-05	0.000209	CcSEcCtD
Ezogabine—Nausea—Gemcitabine—hematologic cancer	4.49e-05	0.000209	CcSEcCtD
Ezogabine—Hyperhidrosis—Prednisone—hematologic cancer	4.47e-05	0.000208	CcSEcCtD
Ezogabine—Vision blurred—Methotrexate—hematologic cancer	4.46e-05	0.000208	CcSEcCtD
Ezogabine—Mental disorder—Epirubicin—hematologic cancer	4.46e-05	0.000207	CcSEcCtD
Ezogabine—Rash—Cisplatin—hematologic cancer	4.44e-05	0.000207	CcSEcCtD
Ezogabine—Dermatitis—Cisplatin—hematologic cancer	4.44e-05	0.000206	CcSEcCtD
Ezogabine—Malnutrition—Epirubicin—hematologic cancer	4.43e-05	0.000206	CcSEcCtD
Ezogabine—Eye disorder—Doxorubicin—hematologic cancer	4.4e-05	0.000205	CcSEcCtD
Ezogabine—Ill-defined disorder—Methotrexate—hematologic cancer	4.4e-05	0.000204	CcSEcCtD
Ezogabine—Feeling abnormal—Betamethasone—hematologic cancer	4.38e-05	0.000204	CcSEcCtD
Ezogabine—Feeling abnormal—Dexamethasone—hematologic cancer	4.38e-05	0.000204	CcSEcCtD
Ezogabine—Malaise—Methotrexate—hematologic cancer	4.27e-05	0.000199	CcSEcCtD
Ezogabine—Dizziness—Etoposide—hematologic cancer	4.27e-05	0.000198	CcSEcCtD
Ezogabine—Muscle spasms—Epirubicin—hematologic cancer	4.26e-05	0.000198	CcSEcCtD
Ezogabine—Vertigo—Methotrexate—hematologic cancer	4.26e-05	0.000198	CcSEcCtD
Ezogabine—Leukopenia—Methotrexate—hematologic cancer	4.24e-05	0.000197	CcSEcCtD
Ezogabine—Dizziness—Prednisolone—hematologic cancer	4.21e-05	0.000196	CcSEcCtD
Ezogabine—Asthenia—Triamcinolone—hematologic cancer	4.2e-05	0.000195	CcSEcCtD
Ezogabine—Nausea—Cisplatin—hematologic cancer	4.19e-05	0.000195	CcSEcCtD
Ezogabine—Vision blurred—Epirubicin—hematologic cancer	4.18e-05	0.000194	CcSEcCtD
Ezogabine—Alopecia—Doxorubicin—hematologic cancer	4.16e-05	0.000194	CcSEcCtD
Ezogabine—Paraesthesia—Prednisone—hematologic cancer	4.15e-05	0.000193	CcSEcCtD
Ezogabine—Mental disorder—Doxorubicin—hematologic cancer	4.13e-05	0.000192	CcSEcCtD
Ezogabine—Ill-defined disorder—Epirubicin—hematologic cancer	4.11e-05	0.000191	CcSEcCtD
Ezogabine—Malnutrition—Doxorubicin—hematologic cancer	4.1e-05	0.000191	CcSEcCtD
Ezogabine—Dyspepsia—Prednisone—hematologic cancer	4.07e-05	0.000189	CcSEcCtD
Ezogabine—Rash—Etoposide—hematologic cancer	4.07e-05	0.000189	CcSEcCtD
Ezogabine—Dermatitis—Etoposide—hematologic cancer	4.07e-05	0.000189	CcSEcCtD
Ezogabine—Rash—Prednisolone—hematologic cancer	4.01e-05	0.000187	CcSEcCtD
Ezogabine—Dermatitis—Prednisolone—hematologic cancer	4.01e-05	0.000186	CcSEcCtD
Ezogabine—Malaise—Epirubicin—hematologic cancer	4e-05	0.000186	CcSEcCtD
Ezogabine—Fatigue—Prednisone—hematologic cancer	3.99e-05	0.000185	CcSEcCtD
Ezogabine—Discomfort—Methotrexate—hematologic cancer	3.98e-05	0.000185	CcSEcCtD
Ezogabine—Vertigo—Epirubicin—hematologic cancer	3.98e-05	0.000185	CcSEcCtD
Ezogabine—Syncope—Epirubicin—hematologic cancer	3.98e-05	0.000185	CcSEcCtD
Ezogabine—Leukopenia—Epirubicin—hematologic cancer	3.97e-05	0.000185	CcSEcCtD
Ezogabine—Constipation—Prednisone—hematologic cancer	3.96e-05	0.000184	CcSEcCtD
Ezogabine—Muscle spasms—Doxorubicin—hematologic cancer	3.94e-05	0.000183	CcSEcCtD
Ezogabine—Confusional state—Methotrexate—hematologic cancer	3.9e-05	0.000181	CcSEcCtD
Ezogabine—Loss of consciousness—Epirubicin—hematologic cancer	3.9e-05	0.000181	CcSEcCtD
Ezogabine—Dizziness—Triamcinolone—hematologic cancer	3.87e-05	0.00018	CcSEcCtD
Ezogabine—Vision blurred—Doxorubicin—hematologic cancer	3.87e-05	0.00018	CcSEcCtD
Ezogabine—Infection—Methotrexate—hematologic cancer	3.84e-05	0.000179	CcSEcCtD
Ezogabine—Nausea—Etoposide—hematologic cancer	3.83e-05	0.000178	CcSEcCtD
Ezogabine—Feeling abnormal—Prednisone—hematologic cancer	3.81e-05	0.000177	CcSEcCtD
Ezogabine—Asthenia—Dexamethasone—hematologic cancer	3.81e-05	0.000177	CcSEcCtD
Ezogabine—Asthenia—Betamethasone—hematologic cancer	3.81e-05	0.000177	CcSEcCtD
Ezogabine—Ill-defined disorder—Doxorubicin—hematologic cancer	3.81e-05	0.000177	CcSEcCtD
Ezogabine—Nervous system disorder—Methotrexate—hematologic cancer	3.79e-05	0.000176	CcSEcCtD
Ezogabine—Thrombocytopenia—Methotrexate—hematologic cancer	3.79e-05	0.000176	CcSEcCtD
Ezogabine—Nausea—Prednisolone—hematologic cancer	3.78e-05	0.000176	CcSEcCtD
Ezogabine—Anxiety—Epirubicin—hematologic cancer	3.76e-05	0.000175	CcSEcCtD
Ezogabine—Hyperhidrosis—Methotrexate—hematologic cancer	3.74e-05	0.000174	CcSEcCtD
Ezogabine—Discomfort—Epirubicin—hematologic cancer	3.73e-05	0.000173	CcSEcCtD
Ezogabine—Malaise—Doxorubicin—hematologic cancer	3.7e-05	0.000172	CcSEcCtD
Ezogabine—Rash—Triamcinolone—hematologic cancer	3.69e-05	0.000172	CcSEcCtD
Ezogabine—Dry mouth—Epirubicin—hematologic cancer	3.69e-05	0.000172	CcSEcCtD
Ezogabine—Dermatitis—Triamcinolone—hematologic cancer	3.69e-05	0.000171	CcSEcCtD
Ezogabine—Vertigo—Doxorubicin—hematologic cancer	3.69e-05	0.000171	CcSEcCtD
Ezogabine—Syncope—Doxorubicin—hematologic cancer	3.68e-05	0.000171	CcSEcCtD
Ezogabine—Leukopenia—Doxorubicin—hematologic cancer	3.67e-05	0.000171	CcSEcCtD
Ezogabine—Confusional state—Epirubicin—hematologic cancer	3.65e-05	0.00017	CcSEcCtD
Ezogabine—Loss of consciousness—Doxorubicin—hematologic cancer	3.61e-05	0.000168	CcSEcCtD
Ezogabine—Infection—Epirubicin—hematologic cancer	3.59e-05	0.000167	CcSEcCtD
Ezogabine—Shock—Epirubicin—hematologic cancer	3.56e-05	0.000166	CcSEcCtD
Ezogabine—Nervous system disorder—Epirubicin—hematologic cancer	3.55e-05	0.000165	CcSEcCtD
Ezogabine—Thrombocytopenia—Epirubicin—hematologic cancer	3.54e-05	0.000165	CcSEcCtD
Ezogabine—Dizziness—Dexamethasone—hematologic cancer	3.51e-05	0.000163	CcSEcCtD
Ezogabine—Dizziness—Betamethasone—hematologic cancer	3.51e-05	0.000163	CcSEcCtD
Ezogabine—Hyperhidrosis—Epirubicin—hematologic cancer	3.5e-05	0.000163	CcSEcCtD
Ezogabine—Anxiety—Doxorubicin—hematologic cancer	3.48e-05	0.000162	CcSEcCtD
Ezogabine—Nausea—Triamcinolone—hematologic cancer	3.48e-05	0.000162	CcSEcCtD
Ezogabine—Paraesthesia—Methotrexate—hematologic cancer	3.47e-05	0.000161	CcSEcCtD
Ezogabine—Discomfort—Doxorubicin—hematologic cancer	3.45e-05	0.00016	CcSEcCtD
Ezogabine—Dyspnoea—Methotrexate—hematologic cancer	3.45e-05	0.00016	CcSEcCtD
Ezogabine—Somnolence—Methotrexate—hematologic cancer	3.44e-05	0.00016	CcSEcCtD
Ezogabine—Dry mouth—Doxorubicin—hematologic cancer	3.42e-05	0.000159	CcSEcCtD
Ezogabine—Dyspepsia—Methotrexate—hematologic cancer	3.4e-05	0.000158	CcSEcCtD
Ezogabine—Confusional state—Doxorubicin—hematologic cancer	3.38e-05	0.000157	CcSEcCtD
Ezogabine—Rash—Betamethasone—hematologic cancer	3.35e-05	0.000156	CcSEcCtD
Ezogabine—Rash—Dexamethasone—hematologic cancer	3.35e-05	0.000156	CcSEcCtD
Ezogabine—Dermatitis—Betamethasone—hematologic cancer	3.35e-05	0.000156	CcSEcCtD
Ezogabine—Dermatitis—Dexamethasone—hematologic cancer	3.35e-05	0.000156	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.34e-05	0.000155	CcSEcCtD
Ezogabine—Fatigue—Methotrexate—hematologic cancer	3.33e-05	0.000155	CcSEcCtD
Ezogabine—Infection—Doxorubicin—hematologic cancer	3.33e-05	0.000155	CcSEcCtD
Ezogabine—Asthenia—Prednisone—hematologic cancer	3.32e-05	0.000154	CcSEcCtD
Ezogabine—Shock—Doxorubicin—hematologic cancer	3.29e-05	0.000153	CcSEcCtD
Ezogabine—Nervous system disorder—Doxorubicin—hematologic cancer	3.28e-05	0.000153	CcSEcCtD
Ezogabine—Thrombocytopenia—Doxorubicin—hematologic cancer	3.28e-05	0.000152	CcSEcCtD
Ezogabine—Paraesthesia—Epirubicin—hematologic cancer	3.25e-05	0.000151	CcSEcCtD
Ezogabine—Hyperhidrosis—Doxorubicin—hematologic cancer	3.24e-05	0.00015	CcSEcCtD
Ezogabine—Dyspnoea—Epirubicin—hematologic cancer	3.23e-05	0.00015	CcSEcCtD
Ezogabine—Somnolence—Epirubicin—hematologic cancer	3.22e-05	0.00015	CcSEcCtD
Ezogabine—Feeling abnormal—Methotrexate—hematologic cancer	3.19e-05	0.000148	CcSEcCtD
Ezogabine—Dyspepsia—Epirubicin—hematologic cancer	3.18e-05	0.000148	CcSEcCtD
Ezogabine—Nausea—Betamethasone—hematologic cancer	3.16e-05	0.000147	CcSEcCtD
Ezogabine—Nausea—Dexamethasone—hematologic cancer	3.16e-05	0.000147	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.12e-05	0.000145	CcSEcCtD
Ezogabine—Fatigue—Epirubicin—hematologic cancer	3.12e-05	0.000145	CcSEcCtD
Ezogabine—Constipation—Epirubicin—hematologic cancer	3.09e-05	0.000144	CcSEcCtD
Ezogabine—Dizziness—Prednisone—hematologic cancer	3.06e-05	0.000142	CcSEcCtD
Ezogabine—Paraesthesia—Doxorubicin—hematologic cancer	3.01e-05	0.00014	CcSEcCtD
Ezogabine—Dyspnoea—Doxorubicin—hematologic cancer	2.98e-05	0.000139	CcSEcCtD
Ezogabine—Feeling abnormal—Epirubicin—hematologic cancer	2.98e-05	0.000139	CcSEcCtD
Ezogabine—Somnolence—Doxorubicin—hematologic cancer	2.98e-05	0.000138	CcSEcCtD
Ezogabine—Dyspepsia—Doxorubicin—hematologic cancer	2.95e-05	0.000137	CcSEcCtD
Ezogabine—Rash—Prednisone—hematologic cancer	2.92e-05	0.000136	CcSEcCtD
Ezogabine—Dermatitis—Prednisone—hematologic cancer	2.91e-05	0.000136	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.89e-05	0.000134	CcSEcCtD
Ezogabine—Fatigue—Doxorubicin—hematologic cancer	2.89e-05	0.000134	CcSEcCtD
Ezogabine—Constipation—Doxorubicin—hematologic cancer	2.86e-05	0.000133	CcSEcCtD
Ezogabine—Asthenia—Methotrexate—hematologic cancer	2.77e-05	0.000129	CcSEcCtD
Ezogabine—Feeling abnormal—Doxorubicin—hematologic cancer	2.76e-05	0.000128	CcSEcCtD
Ezogabine—Nausea—Prednisone—hematologic cancer	2.75e-05	0.000128	CcSEcCtD
Ezogabine—Asthenia—Epirubicin—hematologic cancer	2.6e-05	0.000121	CcSEcCtD
Ezogabine—Dizziness—Methotrexate—hematologic cancer	2.56e-05	0.000119	CcSEcCtD
Ezogabine—Rash—Methotrexate—hematologic cancer	2.44e-05	0.000113	CcSEcCtD
Ezogabine—Dermatitis—Methotrexate—hematologic cancer	2.44e-05	0.000113	CcSEcCtD
Ezogabine—Asthenia—Doxorubicin—hematologic cancer	2.4e-05	0.000112	CcSEcCtD
Ezogabine—Dizziness—Epirubicin—hematologic cancer	2.39e-05	0.000111	CcSEcCtD
Ezogabine—UGT1A3—Metabolism—IDH1—hematologic cancer	2.36e-05	0.000272	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ABCB1—hematologic cancer	2.36e-05	0.000272	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NCOA3—hematologic cancer	2.35e-05	0.000272	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ADCY7—hematologic cancer	2.35e-05	0.000272	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NUP214—hematologic cancer	2.34e-05	0.00027	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTO1—hematologic cancer	2.34e-05	0.000269	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ABCC3—hematologic cancer	2.34e-05	0.000269	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—TXN—hematologic cancer	2.34e-05	0.000269	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—IL6—hematologic cancer	2.33e-05	0.000269	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—IL6—hematologic cancer	2.33e-05	0.000269	CbGpPWpGaD
Ezogabine—Nausea—Methotrexate—hematologic cancer	2.3e-05	0.000107	CcSEcCtD
Ezogabine—UGT1A4—Metabolism—MTR—hematologic cancer	2.29e-05	0.000264	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—MTAP—hematologic cancer	2.29e-05	0.000264	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ABCG2—hematologic cancer	2.29e-05	0.000264	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—NCOR1—hematologic cancer	2.29e-05	0.000264	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GSTM1—hematologic cancer	2.29e-05	0.000264	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—MTAP—hematologic cancer	2.29e-05	0.000264	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—SPHK1—hematologic cancer	2.29e-05	0.000264	CbGpPWpGaD
Ezogabine—Rash—Epirubicin—hematologic cancer	2.28e-05	0.000106	CcSEcCtD
Ezogabine—Dermatitis—Epirubicin—hematologic cancer	2.28e-05	0.000106	CcSEcCtD
Ezogabine—KCNQ3—Developmental Biology—MAPK3—hematologic cancer	2.27e-05	0.000262	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MAPK3—hematologic cancer	2.27e-05	0.000262	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—HDC—hematologic cancer	2.27e-05	0.000262	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ENO2—hematologic cancer	2.25e-05	0.000259	CbGpPWpGaD
Ezogabine—Dizziness—Doxorubicin—hematologic cancer	2.21e-05	0.000103	CcSEcCtD
Ezogabine—KCNQ3—Developmental Biology—TGFB1—hematologic cancer	2.21e-05	0.000254	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TGFB1—hematologic cancer	2.21e-05	0.000254	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—UGT1A1—hematologic cancer	2.2e-05	0.000253	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTT1—hematologic cancer	2.18e-05	0.000251	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—TGFB1—hematologic cancer	2.17e-05	0.00025	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—TGFB1—hematologic cancer	2.17e-05	0.00025	CbGpPWpGaD
Ezogabine—Nausea—Epirubicin—hematologic cancer	2.15e-05	9.99e-05	CcSEcCtD
Ezogabine—UGT1A3—Metabolism—CRABP1—hematologic cancer	2.14e-05	0.000246	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—SLC22A1—hematologic cancer	2.14e-05	0.000246	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—SDC1—hematologic cancer	2.13e-05	0.000246	CbGpPWpGaD
Ezogabine—Rash—Doxorubicin—hematologic cancer	2.11e-05	9.82e-05	CcSEcCtD
Ezogabine—Dermatitis—Doxorubicin—hematologic cancer	2.11e-05	9.81e-05	CcSEcCtD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—hematologic cancer	2.11e-05	0.000243	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ALOX5—hematologic cancer	2.08e-05	0.00024	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CDA—hematologic cancer	2.08e-05	0.000239	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TNF—hematologic cancer	2.06e-05	0.000238	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TNF—hematologic cancer	2.06e-05	0.000238	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—KRAS—hematologic cancer	2.04e-05	0.000236	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—KRAS—hematologic cancer	2.04e-05	0.000236	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—FHL2—hematologic cancer	2.04e-05	0.000235	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—FHL2—hematologic cancer	2.04e-05	0.000235	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—MTHFR—hematologic cancer	2.02e-05	0.000233	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NUP98—hematologic cancer	2.02e-05	0.000232	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—AGRN—hematologic cancer	2e-05	0.000231	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—AGRN—hematologic cancer	2e-05	0.000231	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PC—hematologic cancer	2e-05	0.00023	CbGpPWpGaD
Ezogabine—Nausea—Doxorubicin—hematologic cancer	1.99e-05	9.25e-05	CcSEcCtD
Ezogabine—UGT1A3—Metabolism—ADCY7—hematologic cancer	1.96e-05	0.000226	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NCOA3—hematologic cancer	1.96e-05	0.000226	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NUP214—hematologic cancer	1.94e-05	0.000224	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GBA—hematologic cancer	1.93e-05	0.000223	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SLC35B2—hematologic cancer	1.93e-05	0.000223	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ABCG2—hematologic cancer	1.9e-05	0.00022	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—MTR—hematologic cancer	1.9e-05	0.00022	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—HMMR—hematologic cancer	1.9e-05	0.000219	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—IDH2—hematologic cancer	1.9e-05	0.000219	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—IDH2—hematologic cancer	1.9e-05	0.000219	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—HMMR—hematologic cancer	1.9e-05	0.000219	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ENO2—hematologic cancer	1.87e-05	0.000215	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTT1—hematologic cancer	1.81e-05	0.000209	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CD44—hematologic cancer	1.81e-05	0.000209	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NQO1—hematologic cancer	1.81e-05	0.000209	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.79e-05	0.000206	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ARNTL—hematologic cancer	1.78e-05	0.000206	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ARNTL—hematologic cancer	1.78e-05	0.000206	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—SDC1—hematologic cancer	1.77e-05	0.000204	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—MTAP—hematologic cancer	1.77e-05	0.000204	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—HRAS—hematologic cancer	1.74e-05	0.0002	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—HRAS—hematologic cancer	1.74e-05	0.0002	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CA9—hematologic cancer	1.74e-05	0.0002	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ACP5—hematologic cancer	1.74e-05	0.0002	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CA9—hematologic cancer	1.74e-05	0.0002	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ACP5—hematologic cancer	1.74e-05	0.0002	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CYCS—hematologic cancer	1.71e-05	0.000198	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NCOR2—hematologic cancer	1.71e-05	0.000198	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NCOR2—hematologic cancer	1.71e-05	0.000198	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—HSP90AA1—hematologic cancer	1.7e-05	0.000196	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CG—hematologic cancer	1.7e-05	0.000196	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—TGFB1—hematologic cancer	1.67e-05	0.000193	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—IL6—hematologic cancer	1.66e-05	0.000192	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—IL6—hematologic cancer	1.66e-05	0.000192	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—IDH1—hematologic cancer	1.63e-05	0.000188	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—IDH1—hematologic cancer	1.63e-05	0.000188	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTO1—hematologic cancer	1.61e-05	0.000186	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ABCC3—hematologic cancer	1.61e-05	0.000186	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ABCC3—hematologic cancer	1.61e-05	0.000186	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—TXN—hematologic cancer	1.61e-05	0.000186	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTO1—hematologic cancer	1.61e-05	0.000186	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—TXN—hematologic cancer	1.61e-05	0.000186	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SPHK1—hematologic cancer	1.58e-05	0.000182	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SPHK1—hematologic cancer	1.58e-05	0.000182	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CREBBP—hematologic cancer	1.58e-05	0.000182	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—FHL2—hematologic cancer	1.57e-05	0.000181	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—AGRN—hematologic cancer	1.54e-05	0.000178	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—AKT1—hematologic cancer	1.53e-05	0.000177	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—AKT1—hematologic cancer	1.53e-05	0.000177	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—UGT1A1—hematologic cancer	1.52e-05	0.000175	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTP1—hematologic cancer	1.51e-05	0.000174	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CD44—hematologic cancer	1.51e-05	0.000174	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NQO1—hematologic cancer	1.51e-05	0.000174	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CD—hematologic cancer	1.5e-05	0.000172	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ALB—hematologic cancer	1.48e-05	0.00017	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CRABP1—hematologic cancer	1.48e-05	0.00017	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CRABP1—hematologic cancer	1.48e-05	0.00017	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SLC22A1—hematologic cancer	1.48e-05	0.00017	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SLC22A1—hematologic cancer	1.48e-05	0.00017	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—IDH2—hematologic cancer	1.46e-05	0.000169	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—HMMR—hematologic cancer	1.46e-05	0.000169	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ALOX5—hematologic cancer	1.44e-05	0.000166	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ALOX5—hematologic cancer	1.44e-05	0.000166	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ABCB1—hematologic cancer	1.43e-05	0.000165	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYCS—hematologic cancer	1.42e-05	0.000164	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—HSP90AA1—hematologic cancer	1.42e-05	0.000163	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3R1—hematologic cancer	1.41e-05	0.000163	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NUP98—hematologic cancer	1.39e-05	0.000161	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NUP98—hematologic cancer	1.39e-05	0.000161	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NCOR1—hematologic cancer	1.39e-05	0.00016	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTM1—hematologic cancer	1.39e-05	0.00016	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ARNTL—hematologic cancer	1.38e-05	0.000159	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ADCY7—hematologic cancer	1.35e-05	0.000156	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ADCY7—hematologic cancer	1.35e-05	0.000156	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NCOA3—hematologic cancer	1.35e-05	0.000156	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NCOA3—hematologic cancer	1.35e-05	0.000156	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NUP214—hematologic cancer	1.34e-05	0.000155	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NUP214—hematologic cancer	1.34e-05	0.000155	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CA9—hematologic cancer	1.34e-05	0.000154	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ACP5—hematologic cancer	1.34e-05	0.000154	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.33e-05	0.000153	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NCOR2—hematologic cancer	1.32e-05	0.000152	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ABCG2—hematologic cancer	1.32e-05	0.000152	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ABCG2—hematologic cancer	1.32e-05	0.000152	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—MTR—hematologic cancer	1.32e-05	0.000152	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—MTR—hematologic cancer	1.32e-05	0.000152	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CB—hematologic cancer	1.3e-05	0.00015	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ENO2—hematologic cancer	1.29e-05	0.000149	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ENO2—hematologic cancer	1.29e-05	0.000149	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—IDH1—hematologic cancer	1.26e-05	0.000145	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTP1—hematologic cancer	1.26e-05	0.000145	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTT1—hematologic cancer	1.25e-05	0.000144	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTT1—hematologic cancer	1.25e-05	0.000144	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ABCC3—hematologic cancer	1.24e-05	0.000143	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TXN—hematologic cancer	1.24e-05	0.000143	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTO1—hematologic cancer	1.24e-05	0.000143	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.23e-05	0.000142	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—MTHFR—hematologic cancer	1.23e-05	0.000141	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SDC1—hematologic cancer	1.22e-05	0.000141	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SDC1—hematologic cancer	1.22e-05	0.000141	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SPHK1—hematologic cancer	1.22e-05	0.00014	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ABCB1—hematologic cancer	1.19e-05	0.000137	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—UGT1A1—hematologic cancer	1.17e-05	0.000135	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.17e-05	0.000135	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTM1—hematologic cancer	1.15e-05	0.000133	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NCOR1—hematologic cancer	1.15e-05	0.000133	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.15e-05	0.000133	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SLC22A1—hematologic cancer	1.14e-05	0.000131	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CRABP1—hematologic cancer	1.14e-05	0.000131	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTEN—hematologic cancer	1.13e-05	0.00013	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ALOX5—hematologic cancer	1.11e-05	0.000128	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.1e-05	0.000127	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—EP300—hematologic cancer	1.07e-05	0.000124	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NUP98—hematologic cancer	1.07e-05	0.000124	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NCOA3—hematologic cancer	1.04e-05	0.00012	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ADCY7—hematologic cancer	1.04e-05	0.00012	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CD44—hematologic cancer	1.04e-05	0.00012	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CD44—hematologic cancer	1.04e-05	0.00012	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NQO1—hematologic cancer	1.04e-05	0.00012	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NQO1—hematologic cancer	1.04e-05	0.00012	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NUP214—hematologic cancer	1.04e-05	0.000119	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CG—hematologic cancer	1.03e-05	0.000119	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—MTHFR—hematologic cancer	1.02e-05	0.000118	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.02e-05	0.000117	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—MTR—hematologic cancer	1.01e-05	0.000117	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ABCG2—hematologic cancer	1.01e-05	0.000117	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ENO2—hematologic cancer	9.95e-06	0.000115	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYCS—hematologic cancer	9.84e-06	0.000113	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYCS—hematologic cancer	9.84e-06	0.000113	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—HSP90AA1—hematologic cancer	9.78e-06	0.000113	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—HSP90AA1—hematologic cancer	9.78e-06	0.000113	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTT1—hematologic cancer	9.65e-06	0.000111	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CREBBP—hematologic cancer	9.55e-06	0.00011	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SDC1—hematologic cancer	9.43e-06	0.000109	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CD—hematologic cancer	9.06e-06	0.000104	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ALB—hematologic cancer	8.94e-06	0.000103	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	8.8e-06	0.000101	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTP1—hematologic cancer	8.67e-06	0.0001	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTP1—hematologic cancer	8.67e-06	0.0001	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CG—hematologic cancer	8.57e-06	9.88e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3R1—hematologic cancer	8.55e-06	9.86e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	8.39e-06	9.68e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ABCB1—hematologic cancer	8.21e-06	9.47e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ABCB1—hematologic cancer	8.21e-06	9.47e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CD44—hematologic cancer	8.02e-06	9.24e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NQO1—hematologic cancer	8.02e-06	9.24e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTM1—hematologic cancer	7.97e-06	9.19e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTM1—hematologic cancer	7.97e-06	9.19e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NCOR1—hematologic cancer	7.97e-06	9.19e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NCOR1—hematologic cancer	7.97e-06	9.19e-05	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CA—hematologic cancer	7.94e-06	9.16e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CREBBP—hematologic cancer	7.94e-06	9.16e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CB—hematologic cancer	7.9e-06	9.1e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYCS—hematologic cancer	7.59e-06	8.75e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—HSP90AA1—hematologic cancer	7.54e-06	8.69e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CD—hematologic cancer	7.53e-06	8.68e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ALB—hematologic cancer	7.43e-06	8.57e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3R1—hematologic cancer	7.11e-06	8.2e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—MTHFR—hematologic cancer	7.04e-06	8.12e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—MTHFR—hematologic cancer	7.04e-06	8.12e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTEN—hematologic cancer	6.82e-06	7.87e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTP1—hematologic cancer	6.69e-06	7.71e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CB—hematologic cancer	6.56e-06	7.57e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—EP300—hematologic cancer	6.51e-06	7.5e-05	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—AKT1—hematologic cancer	6.49e-06	7.48e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ABCB1—hematologic cancer	6.33e-06	7.3e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	6.21e-06	7.16e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTM1—hematologic cancer	6.14e-06	7.08e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NCOR1—hematologic cancer	6.14e-06	7.08e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CG—hematologic cancer	5.92e-06	6.82e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CG—hematologic cancer	5.92e-06	6.82e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTEN—hematologic cancer	5.67e-06	6.54e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CREBBP—hematologic cancer	5.49e-06	6.33e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CREBBP—hematologic cancer	5.49e-06	6.33e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—MTHFR—hematologic cancer	5.43e-06	6.26e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—EP300—hematologic cancer	5.41e-06	6.24e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CD—hematologic cancer	5.2e-06	6e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CD—hematologic cancer	5.2e-06	6e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ALB—hematologic cancer	5.14e-06	5.92e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ALB—hematologic cancer	5.14e-06	5.92e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3R1—hematologic cancer	4.91e-06	5.67e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3R1—hematologic cancer	4.91e-06	5.67e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CA—hematologic cancer	4.81e-06	5.55e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CG—hematologic cancer	4.56e-06	5.26e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CB—hematologic cancer	4.54e-06	5.23e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CB—hematologic cancer	4.54e-06	5.23e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CREBBP—hematologic cancer	4.23e-06	4.88e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CD—hematologic cancer	4.01e-06	4.62e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CA—hematologic cancer	4e-06	4.61e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ALB—hematologic cancer	3.96e-06	4.57e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—AKT1—hematologic cancer	3.93e-06	4.53e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTEN—hematologic cancer	3.92e-06	4.52e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTEN—hematologic cancer	3.92e-06	4.52e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3R1—hematologic cancer	3.79e-06	4.37e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—EP300—hematologic cancer	3.74e-06	4.31e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—EP300—hematologic cancer	3.74e-06	4.31e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CB—hematologic cancer	3.5e-06	4.03e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—AKT1—hematologic cancer	3.27e-06	3.77e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTEN—hematologic cancer	3.02e-06	3.48e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—EP300—hematologic cancer	2.88e-06	3.32e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CA—hematologic cancer	2.76e-06	3.19e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CA—hematologic cancer	2.76e-06	3.19e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—AKT1—hematologic cancer	2.26e-06	2.6e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—AKT1—hematologic cancer	2.26e-06	2.6e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CA—hematologic cancer	2.13e-06	2.46e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—AKT1—hematologic cancer	1.74e-06	2.01e-05	CbGpPWpGaD
